PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
10.21203/rs.3.rs-1259287/v12022PIK3CA Mutation is Associated with Poor Response to HER2-Targeted Therapy in Breast Cancer PatientsJu Won Kim, Ah Reum Lim, Ji Young You, Jung Hyun Lee, Sung Eun Song, Nam Kwon Lee, Seung Pil Jung, Kyu Ran Cho, Cheol Yong Kim, Kyong Hwa PARKhttps://www.researchsquare.com/article/rs-1259287/v1, https://www.researchsquare.com/article/rs-1259287/v1.html
Cancer Research and Treatment10.4143/crt.2022.2212023552531-541PIK3CA Mutation is Associated with Poor Response to HER2-Targeted Therapy in Breast Cancer PatientsJu Won Kim, Ah Reum Lim, Ji Young You, Jung Hyun Lee, Sung Eun Song, Nam Kwon Lee, Seung Pil Jung, Kyu Ran Cho, Cheol Yong Kim, Kyong Hwa Parkhttp://e-crt.org/upload/pdf/crt-2022-221.pdf, http://e-crt.org/journal/view.php?doi=10.4143/crt.2022.221, http://e-crt.org/upload/pdf/crt-2022-221.pdf
Breast Cancer Research and Treatment10.1007/s10549-015-3480-620151523463-476The predictive and prognostic role of phosphatase phosphoinositol-3 (PI3) kinase (PIK3CA) mutation in HER2-positive breast cancer receiving HER2-targeted therapy: a meta-analysisEzzeldin M. Ibrahim, Ghieth A. Kazkaz, Mubarak M. Al-Mansour, Meteb E. Al-Foheidihttp://link.springer.com/content/pdf/10.1007/s10549-015-3480-6.pdf, http://link.springer.com/article/10.1007/s10549-015-3480-6/fulltext.html, http://link.springer.com/content/pdf/10.1007/s10549-015-3480-6
Journal of Modern Oncology10.26442/18151434.2021.2.2009232021232269-274PIK3CA mutation: changing the paradigm of HR+ HER2-negative metastatic breast cancer therapy. Review of the Novartis Pharma satellite symposium, held as part of a virtual forum dedicated to the diagnosis and treatment of patients with hormone-dependent HER2-negative advanced breast cancer with a PIK3CA gene mutation. April 23, 2021https://modernonco.orscience.ru/1815-1434/article/viewFile/77894/58478, https://modernonco.orscience.ru/1815-1434/article/viewFile/77894/58478
Her2-Positive Breast Cancer10.1016/b978-0-323-58122-6.00011-82019171-178Noncardiac Toxicity of HER2-Targeted TherapyAashini Masterhttps://api.elsevier.com/content/article/PII:B9780323581226000118?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:B9780323581226000118?httpAccept=text/plain
Handbook of HER2-Targeted Agents in Breast Cancer10.1007/978-3-319-28216-9_3201629-49HER2-positive breast cancer: neoadjuvant and adjuvant therapyNadia Harbeckhttp://link.springer.com/content/pdf/10.1007/978-3-319-28216-9_3
Handbook of HER2-targeted agents in breast cancer10.1007/978-1-907673-94-8_3201325-42HER2-Positive Breast Cancer: Adjuvant and Neoadjuvant TherapyNadia Harbeckhttps://link.springer.com/content/pdf/10.1007/978-1-907673-94-8_3
Annals of Oncology10.1093/annonc/mdz268.022201930v768-v769Breast cancer organoids model treatment response of HER2 targeted therapy in HER2-mutant breast cancerX. Li, B. Pan, J. Ma, Z. Zhao, M. Lihttps://api.elsevier.com/content/article/PII:S0923753419600244?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753419600244?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/30/Supplement_5/mdz268.022/30084842/mdz268.022.pdf
Journal of Breast Cancer10.4048/jbc.2014.17.3.2872014173287Combined Antiangiogenic and Mammalian Target of Rapamycin Inhibitor Targeted Therapy in Metaplastic Breast Cancer Harboring aPIK3CAMutationRishi Agarwal, Kimberly Koenig, Eric Rohren, Vivek Subbiahhttps://synapse.koreamed.org/DOIx.php?id=10.4048/jbc.2014.17.3.287, https://synapse.koreamed.org/pdf/10.4048/jbc.2014.17.3.287, https://ejbc.kr/DOIx.php?id=10.4048/jbc.2014.17.3.287
Translational Oncology10.1016/j.tranon.2023.101738202337101738Association of PIK3CA mutation with outcomes in HER2-positive breast cancer treated with anti-HER2 therapy: A meta-analysis and bioinformatic analysis of TCGA‑BRCA dataHaizhu Chen, Xingbin Hu, Daquan Wang, Ying Wang, Yunfang Yu, Herui Yaohttps://api.elsevier.com/content/article/PII:S1936523323001249?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1936523323001249?httpAccept=text/plain